Compare LOVE & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOVE | TNXP |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.4M | 199.7M |
| IPO Year | 2018 | 2008 |
| Metric | LOVE | TNXP |
|---|---|---|
| Price | $14.48 | $10.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | 283.9K | ★ 413.4K |
| Earning Date | 06-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $697,115,000.00 | $13,107,000.00 |
| Revenue This Year | $4.63 | $558.11 |
| Revenue Next Year | $6.40 | $38.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.42 | ★ 29.85 |
| 52 Week Low | $10.33 | $9.40 |
| 52 Week High | $19.25 | $25.69 |
| Indicator | LOVE | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 42.68 | 33.24 |
| Support Level | $12.54 | $10.03 |
| Resistance Level | $16.47 | $12.99 |
| Average True Range (ATR) | 0.87 | 0.55 |
| MACD | -0.11 | -0.28 |
| Stochastic Oscillator | 32.40 | 10.01 |
The Lovesac Co designs, manufactures and sells alternative furniture which is comprised of modular couches called sactionals and premium foam beanbag chairs called sacs. It also offers other accessories such as sactional-specific drink holders, Footsac blankets, decorative pillows, fitted seat tables, and ottomans. Its products are sold across the United States through its website or company-owned retail stores which are used in homes and offices. The majority of the firm's revenue is derived from the sale of Sactionals.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.